Danaher Q3 2025 Financial Results and Outlook FAQ
Summary
Danaher Corporation reported strong third quarter 2025 results with revenue growth and exceeded expectations, while maintaining its full-year earnings guidance and expecting continued low-single digit core revenue growth.
What were Danaher’s key financial results for Q3 2025?
Danaher reported net earnings of $908 million ($1.27 per diluted share), revenues of $6.1 billion (4.5% year-over-year growth), operating cash flow of $1.7 billion, and non-GAAP adjusted diluted net earnings per common share of $1.89.
How did Danaher’s revenue performance compare to the previous year?
Revenues increased 4.5% year-over-year to $6.1 billion, while non-GAAP core revenue increased 3.0% year-over-year.
What factors contributed to Danaher’s better-than-expected performance?
According to CEO Rainer M. Blair, DBS-driven execution, continued momentum in the bioprocessing business, and better-than-anticipated respiratory revenue at Cepheid enabled the company to exceed expectations.
What is Danaher’s full-year 2025 earnings guidance?
Danaher is maintaining its full-year adjusted diluted net earnings per common share guidance range of $7.70 to $7.80.
What is the company’s revenue growth expectation for full year 2025?
The company expects non-GAAP core revenue to grow low-single digits year-over-year for the full year 2025.
Why doesn’t Danaher provide GAAP reconciliations for its full-year outlook?
The company states that additional elements affecting GAAP measures are difficult to predict and estimate, often dependent on future events that may be uncertain or outside their control, and their impact could be material to GAAP results.
What is Danaher’s strategic focus according to the CEO?
Danaher remains focused on delivering value for customers, associates, and shareholders by investing in breakthrough innovation, enhancing commercial execution, and driving meaningful productivity gains across businesses.
What is Danaher’s business focus and mission?
Danaher is a leading global life sciences and diagnostics innovator committed to accelerating science and technology to improve human health, helping enable faster, more accurate diagnoses and reducing time and cost for developing life-changing therapies.
When does the reported quarter cover?
The reported results cover the quarter ended September 26, 2025.
Where can I find more information about Danaher?
More information about Danaher can be found at their website: www.danaher.com.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at citybiz
Article Control ID: 259249